Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasNeuro-OncologyDiseaseAcute Lymphoblastic LeukaemiaMalignant MeningitisNHL, B-Cell Type, Burkitt's LymphomaSubgroupB-ALLLeukemic MeningitisICD10C79.3C83.7C91.0-MeSHBurkitt LymphomaMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceDA-EPOCH-R(R), Burkitt's lymphomaR-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).ChemotherapyChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateNo. Substances123 RadiotherapySupportive therapySupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseReinductionTherapy intentioncurativeRisksEmetogenicityEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorGriffin TCGökbuget NKopmar NRausch CRoschewski MDiseaseAkute lymphatische Leukämie, B/T lymphoblastisches LymphomBurkitt-Lymphom, ZNS-Befall vor Beginn der TherapieHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstliniePrimär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2OriginDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003Lymphoid Malignancies Branch, National Cancer Institute, BethesdaMemorial Hospital of South Bend, South BendProtocols in Revision 5 protocols foundProtocols under revision.Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602 V2.0)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575 V1.0)Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231 V1.1)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240 V1.1)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876 V1.1)
